OncoResponse
OncoResponse is a biotech company developing antibody-based cancer immunotherapies.
Facts
- HQ
- Seattle, US
- Sectors
- Research
- Founded
- 2016
- Type
- Corporation Seattle business license
- Employees
- 9
- Registered name
- OncoResponse Inc Seattle business license
- Stage
- Series D
- Members see funding amounts. .
Is this your organization? Claim it
OncoResponse raises $150M total, closes $6M Series D in April 2025; backed by ARE, Rice University, Takeda
OncoResponse, headquartered in Seattle, has raised $150M total with a recorded $6M Series D round in April 2025 and is backed by investors including ARE, Rice University, and Takeda Pharmaceuticals.
OncoResponse Raises $27M to Advance Antibody-Based Cancer Immunotherapies OR502 and OR2805
Seattle biotech firm OncoResponse secured $27 million to advance testing of its antibody-based cancer immunotherapy candidates OR502 and OR2805. The funding includes a $13 million grant from the Cancer Prevention and Research Institute of Texas and $14 million from investors led by RiverVest Venture Partners.
Juno Therapeutics’ 2013 launch spurred Seattle cell-therapy boom after $300M+ raise and $9B+ 2018 sale to Celgene
Juno Therapeutics, founded in 2013, accelerated cell therapy development by raising over $300 million, going public within a year, and selling to Celgene for more than $9 billion in 2018, and its alumni spawned many Seattle-area biotech startups. The company’s success attracted capital, validated Seattle as a cellular and gene therapy hub, and influenced the region’s biotech entrepreneurship and leadership.
See all 5 stories, episodes and videos about OncoResponse.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Clifford Stocks Founder, Executive Officer, Director, Chief Executive Officer